Related Experiment Video
Updated: Apr 1, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
The eradication of HCV
Stella De Nicola1, Massimo Colombo
1Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy - massimo.colombo@unimi.it.
Insights
Hepatitis C virus (HCV) infection is a curable disease, with new direct-acting antiviral agents (DAAs) achieving high sustained viral response rates. Achieving global HCV eradication requires increased diagnosis, treatment access, and targeted prevention strategies.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection impacts approximately 3% of the global population, potentially leading to severe liver conditions like cirrhosis and hepatocellular carcinoma.
- Despite challenges, HCV is a curable infection with significant advancements in diagnostics and therapeutics since the virus's discovery.
Purpose of the Study:
- To highlight the impact of direct-acting antiviral agents (DAAs) on Hepatitis C virus (HCV) treatment outcomes.
- To outline the necessary steps towards global HCV eradication, including diagnosis, treatment, and prevention.
Main Methods:
- Review of recent advancements in Hepatitis C virus (HCV) diagnostics and therapeutics.
- Analysis of the efficacy of direct-acting antiviral agents (DAAs) across different HCV genotypes and patient populations.
- Discussion of strategies for HCV control and eradication.
Main Results:
- Direct-acting antiviral agents (DAAs) offer short, well-tolerated, all-oral regimens with high sustained viral response (SVR) rates for all HCV genotypes.
- DAAs have expanded treatment options to patients previously considered difficult to treat or contraindicated due to advanced cirrhosis.
- Significant progress has been made, but challenges remain in patient identification, therapy access, and targeting high-risk groups.
Conclusions:
- Hepatitis C virus (HCV) is now a curable infection, with DAAs revolutionizing treatment outcomes.
- Achieving global HCV eradication necessitates a comprehensive strategy encompassing diagnosis, widespread treatment access, and targeted prevention of transmission.
- A concerted global effort is crucial to control morbidity/mortality, reduce incidence, and ultimately eliminate HCV worldwide.
Abstract:
Hepatitis C virus (HCV) infection is a major health problem that affects about 3% of the world's population. Chronic infection can evolve into cirrhosis, end-stage liver disease and hepatocellular carcinoma. Since the discovery of the virus, great advances were made in its diagnostics and therapeutics. HCV has the peculiarity of being a curable infection, as persistent virus eradication can be achieved through therapy. The recent advent of direct-acting antiviral agents (DAAs), which can be combined to provide short and well-tolerated all-oral regimens, has allows higher rates of sustained viral response (SVR) for all HCV genotypes, also in patients previously considered as "difficult to treat" and in patients with advanced cirrhosis, in whom antiviral treatment was contraindicated in the past. While on the one hand this could make eradicating HCV a reality, still several other measures are necessary for this goal to be attained, including HCV-infected patients identification, broad access to therapy and need to target categories at highest risk of HCV infection and transmission. Ideally in the coming decades we would like to first control the disease by reducing morbidity and mortality, subsequently to reduce transmission and incidence to an acceptable level, and finally to achieve virus eradication worldwide. But this ideal progression requires a huge effort in terms of diagnosis, treatment and prevention of disease transmission.
Related Concept Videos
01:25Hepatitis
01:10Retrovirus Life Cycles
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
02:33Retroviruses